Brexin 20mg 20 tablets — Made in Italy — Free Delivery

Product description 

Brexin® tablets are used for symptomatic treatment:

• osteoarthritis;
• rheumatoid arthritis;
• ankylosing spondylitis (ankylosing spondylitis).

Because of its safety profile, piroxicam is not the first choice if other non-steroidal antirheumatic preparations are indicated. The decision to prescribe piroxicam should be based on an assessment of the individual's overall risk to the patient.

Since a constant effective concentration of piroxicam is achieved only 5-10 days after the start of the usual daily dose, this preparation is not used as a starting therapy for diseases requiring a quick onset of action.

Compound

The active ingredient is piroxicam (one tablet contains piroxicam-betadex 191.2 mg, which is equivalent to 20 mg of piroxicam).

Excipients: lactose, monohydrate; pregelatinized starch; sodium starch glycolate (type A); magnesium stearate; colloidal aqueous silicon dioxide; crospovidone.

Contraindications

• hypersensitivity to acetylsalicylic acid and other non-steroidal anti-inflammatory preparations (cross-sensitivity), with the simultaneous use of which there have been cases of asthma, urticaria, rhinitis or Quincke's edema;
• hypersensitivity to the active substance or to excipients, previous skin reactions (regardless of severity) in response to the use of piroxicam and other antirheumatic preparations and non-steroidal anti-inflammatory preparations (NSAIDs), other preparations;
• a history of gastrointestinal ulcers, bleeding and perforation;
• gastrointestinal disorders leading to bleeding, such as ulcerative colitis, Crohn's disease, gastrointestinal cancer or diverticulitis in history;
• an ulcer in the acute stage, inflammatory diseases of the gastrointestinal tract or gastrointestinal bleeding;
• simultaneous use with other NSAIDs, including selective COX-2 inhibitors and acetylsalicylic acid in analgesic doses;
• simultaneous use with anticoagulants;
• previous serious allergic reactions of any type to preparations, especially skin reactions such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis;
• violation of hematopoiesis;
• hemorrhagic diathesis;
• cerebrovascular or other active bleeding;
• severe renal and hepatic impairment;
• severe heart failure.

Mode of application

"Brexin®" should be used once a day. The tablet is intended for oral administration. The dividing line on the tablet is only for dividing for easy swallowing, not for dividing into equal parts. To split a tablet, place it on a flat surface with the separation line facing up and press lightly with your thumb.

Piroxicam should be prescribed by a physician experienced in the diagnostic evaluation and treatment of patients with inflammatory or degenerative rheumatic diseases.

For adults, the maximum recommended daily dose is 20 mg.

Adverse reactions can be minimized by using the lowest effective dose for the short period of time necessary to control symptoms.

The benefit of treatment and the tolerability of the preparation should be determined within 14 days. If the need for continued treatment is determined, this reassessment should be done more frequently. When prescribing piroxicam, it should be borne in mind that its use raises the risk of gastrointestinal complications, therefore, the possible need for combination therapy with gastroprotective preparations (misoprostol or proton pump inhibitors) should be considered, especially in elderly patients.

Application features

Pregnant

Piroxicam is contraindicated in pregnant women, women planning pregnancy, and women who are breastfeeding.

Children

The preparation should not be used in children, since the dosage and indications for children have not been established.

Drivers

Piroxicam can impair concentration, which can adversely affect the ability to drive and perform actions that require rapid motor reactions.

Overdose

Frequent overdose symptoms are headache, vomiting, drowsiness, dizziness and loss of consciousness.

In case of overdose, supportive and symptomatic treatment is prescribed. Although no specific studies have been carried out so far, hemodialysis is ineffective in promoting the elimination of piroxicam because the preparation is highly binding to plasma proteins.

Side effects

The most commonly reported adverse reactions are from the gastrointestinal tract. Ulcers and gastrointestinal perforations or bleeding, sometimes fatal, may occur, especially in elderly patients.

Storage conditions

Store in its original packaging at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life is 3 years.